期刊
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
卷 28, 期 2, 页码 217-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2013.11.001
关键词
Sickle cell; 5-HMF; Antisickling; R state; Hemoglobin allosteric effectors
资金
- AesRx, LLC
- Virginia Commonwealth University Presidential Research Initiative Program Award
- National Cancer Institute [CA 16059-28]
- National Heart, Lung and Blood Institute Division of Intramural Research [1-ZIA-HL006149-01]
- National Center for Advancing Translational Sciences Therapeutics for Rare and Neglected Diseases Program [1-ZIB-TR000002-01]
The pathophysiology of sickle cell disease involves the polymerization of sickle hemoglobin in its T state, which develops under low oxygen saturation. One therapeutic strategy is to develop pharmacologic agents to stabilize the R state of hemoglobin, which has higher oxygen affinity and is expected to have slower kinetics of polymerization, potentially delaying the sickling of red cells during circulation. This strategy has stimulated the investigation of aromatic aldehydes, aspirin derivatives, thiols, and isothiocyanates that can stabilize the R state of hemoglobin in vitro. One representative aromatic aldehyde agent, 5-hydoxyrnethyl-2-furfural, protects sickle cell mice from the effects of hypoxia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据